Literature DB >> 3902978

A triple antibody assay for the quantitation of plasma IgG subclass antibodies to acetylcholine receptors in patients with myasthenia gravis.

F C Nielsen, A Rødgaard, R Djurup, F Somnier, S Gammeltoft.   

Abstract

Monoclonal anti-human IgG subclass antibodies have been used in an immunoprecipitation assay for the determination of anti-acetylcholine receptor IgG subclasses in plasma from patients with myasthenia gravis. Solubilized acetylcholine receptors labelled with 125I-alpha-bungarotoxin were incubated with patient plasma. Monoclonal mouse antibodies to human IgG subclasses 1-4 were added to the incubation and finally precipitated with anti-mouse IgG antibody. A maximal IgG subclass precipitation of 62-76% was determined with 125I-labelled myeloma IgG subclasses 1-4 added to normal human plasma. The anti-IgG subclass antibodies were added in excess which ensured that the precipitation of IgG2, IgG3 or IgG4 were unchanged, and that of IgG1 was only reduced by 17%, when the plasma IgG concentration was increased by a factor of two. The anti-IgG subclass antibodies were highly specific for their complementary subclasses. Determination of the IgG subclass of the anti-acetylcholine receptor antibodies from 8 patients with myasthenia gravis showed that IgG1 and IgG3 antibodies are predominant. This may support the hypothesis that complement mediated lysis of the neuromuscular end-plate plays a pathogenetic role in myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3902978     DOI: 10.1016/0022-1759(85)90247-9

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Anti-mitochondrial antibody IgG subclass distribution and affinity in primary biliary cirrhosis.

Authors:  L Zhang; A P Weetman; D R Jayne; I Turner; S J Yeaman; M F Bassendine; D B Oliveira
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

3.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

4.  Congenital myasthenic syndrome in the dog breed Gammel Dansk Hønsehund: clinical, electrophysiological, pharmacological and immunological comparison with acquired myasthenia gravis.

Authors:  A Flagstad; W Trojaborg; S Gammeltoft
Journal:  Acta Vet Scand       Date:  1989       Impact factor: 1.695

5.  Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

Authors:  A Rødgaard; F C Nielsen; R Djurup; F Somnier; S Gammeltoft
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

6.  Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members.

Authors:  R Maran; M Dueymes; Y Adler; Y Shoenfeld; P Youinou
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.